

Vineet Laboratories Limited

Regd.Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad. CIN- L24304TG2016PLC112888

Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

July 22, 2025

To The General Manager, Department of Corporate Services, **BSE Limited.** P.J. Towers, Dalal Street, Mumbai-400 001.

To The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, 5th Floor, Plot No - C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai -400 051.

Scrip Code - 543298

Scrip Code - VINEETLAB

Dear Sir/Ma'am.

Sub: Outcome of Board Meeting held on Tuesday, July 22, 2025 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of the company in its meeting held today i.e., on July 22, 2025 has:

Considered and approved the Unaudited Standalone Financial Results of the company for the first quarter ended on June 30, 2025 along with the Limited Review Report submitted by the Statutory Auditors.

Please find enclosed the unaudited Standalone financial results under IndAS for the quarter ended June 30, 2025, together with the Limited Review Report, as approved by the Board today. The financial results are also being made available on the Company's website at www.vineetlabs.co.in.

The Board Meeting commenced at 02:45 PM and concluded at 04:30 PM.

Kindly take this information on records.

Thanking you, Best Regards,

For Vineet Laboratories Limited

Gaddam Venkata Ramana Managing Director

DIN: 00031873

VINEET LABORATORIES LIMITED CIN:L24304TG2016PLC112888

SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.

(All amounts are in INR Lakh except share data or unless otherwise stated)
Statement of Unaudited Financial Results for the Quarter and period ended June 30,2025

S No	Particulars	Quarter ended June 30,2025	Quarter ended March 31,2025	June 30,2024	Year ended March 31,2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from operations				
	a) Net Sales/income from operations	744.18	1,407.65	2,386.16	7,499.50
	Total income from operations	744.18	1,407.65	2,386.16	7,499.50
п	Other income	1.81	138.14	37.26	198.68
ш	Total Income (I + II)	745.98	1,545.79	2,423.42	7,698.18
VI	Expenses				
	a) Cost of materials Consumed	1,200.92	1,270.66	1,673.87	6,376.84
	b) Changes in inventories of finished goods, work-in progress and stock-in-trade(increase)/decrease	-739.72	786.34	222.10	647.00
	c) Employee benefits expenses	105.96	135.08	147.82	533.58
	d) Finance cost	61.22	89.99	113.65	397.76
	e) Depreciation and amortisation expenses	62.54	65.74	60.86	250.16
- 3	f) Other expenses	145.23	320.11	421.88	1,570.39-
	Total expenses	836.14	2,667.92	2,640.18	9,775.73
V	Profit/(loss) before exceptional items and tax (III - IV) Exceptional itmes	(90.16)	(1,122.13)	(216.76)	(2,077.55)
VII	Profit/(loss) before Tax (V -VI)	(90.16)	(1,122.13)	(216.76)	(2,077.55)
VIII	Tax expense :	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VIII	a. Current tax (net)				
	b. Deferred tax(net)	(3.55)	(69.62)	(0.70)	(58.45)
	Total tax expense	(3.55)	(69.62)	(3.70) (3.70)	(
1	Total tax expense	(3.55)	(03.02)	(3.70)	(58.45)
IX	Profit/(loss) for the period (VII-VIII)	(86.61)	(1052.51)	(213.07)	(2,019.10)
x	Other comprehensive income(OCI)				1
	a) (i) Items that will not be reclassified to profit or loss	0	15.29		15.29
	(ii) Income tax relating to items that will not be				ñ-
	reclassified to profit or loss	0	(3.85)	-	(3.85)
	b) (i) Items that will be reclassified to profit or loss				

Notes

χı

XII

XIII

XIV

b) The company operates in one reportable business segment i.e. Active pharmaceuticals ingredient and intermediates. Hence segmental reporting as per Ind AS 108 is not applicable.

c) The results for the Quarter 30th June, 2025 are also available on website of BSE Limited, NSE Limited and on the Company's website.

(ii) Income tax relating to items that will be reclassified

Paid Up Equity Share Capital (Face Value of Rs.10/- each)

Total comprehensive income/(loss) net of tax for the Period/year (IX+X))

Total other comprehensive income/(loss)

Earnings per equity share (of Rs. 10/- each)

: (not annualised for the quarters)

to profit or loss

Other equity

(i) Basic

(ii) Diluted

d) Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation.

Date: 22-07-2025 Place :Hyderabad. For and onbehalf of the Board

11.44

(213.07)

921.90

(2.31)

(2.31)

(1041.08)

921.90

(11.42)

(11.42)

(86.61)

921.90

(0.94)

(0.94)

G. Venkata Ramana Managing Director DIN: 00031873 HYDERABAD

11.44

(2007.67)

921.90

542.86

(21.90)

(21.90)

a) The above statement of un audited financial results of Vineet Laboratories Limited ("the Company"), which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on July 22nd, 2025. The Statutory Auditors have issued an unqualified report thereon.

Balance sheet for the year ended 30 June 2025

(All amounts are in INR Lakhs except share data or unless otherwise stated)

	Notes	As	at
		30 June 2025	31 March 2025
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	2,483.34	2,545.88
(b) Financial assets			
(i) Investments	4	22.44	20.63
(ii) Other financial assets	5	80.09	80.69
(c) Other non-current assets	6	68.02	67.43
		2,653.89	2,714.64
Current assets	- 1		
(a) Inventories	7	5,009.91	4,997.06
(b) Financial assets			
(i) Trade receivables	8	825.59	1,324.71
(ii) Cash and cash equivalents	9	20.42	30.68
(iii) Bank balances other than (ii) above	10	36.23	36.23
(iv) Other financial assets	5	-	-
(c) Other current assets	6	308.35	350.71
10/ 01/10/ 00/10/10		6,200.50	6,739.38
Total assets		8,854.38	9,454.01
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital		921.90	921.90
(b) Other equity	12	460.10	542.86
		1,382.00	1,464.76
Liabilities			
Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	13	451.35	378.59
(b) Provisions	14	124.21	80.43
(c) Deferred tax liabilities(Net)	s(Net) 11 12 13 14 15 13 14 15 13	83.94	91.34
		659.50	550.36
Current liabilities			
(a) Financial liabilities			
(i) Borrowings	13	3,499.47	3,626.12
(ii) Trade payables	16		
Total outstanding dues of micro and small enterprises;		898.47	621.99
Total outstanding dues of creditors other than micro and small enterprises		2,127.78	2,739.22
(iii) Other financial liabilities	17	10.36	5.22
(b) Other current liabilities	18	276.80	402.56
(c) Provisions	14		43.78
(d) Current tax liabilities (net)	19		-
		6,812.88	7,438.89
Total equity and liabilities		8,854.38	9,454.01

For and onbehalf of the Board

HYDERABAD

G. Venkata Ramana Managing Director

DIN: 00031873

Place: Hyderabad Date: 22-07-2025

Statement of Profit and Loss for the year ended 30 June 2025

(All amounts are in INR Lakhs except share data or unless otherwise stated)

Particulars	Notes	For the pe	For the period ended		
		30 June 2025	31 March 2025		
Income					
Revenue from operations	20	744.18	7,499.50		
Other income	21	1.81	198.68		
Total income		745.98	7,698.18		
Expenses					
Cost of material consumed	22	1,200.92	6,376.84		
Changes in inventories of stock-in -trade	23	(739.72)	647.00		
Employee benefits expense	24	105.96	533.58		
Finance costs	25	61.22	397.76		
Depreciation and amortisation expense	26	62.54	250.16		
Other expenses	27	145.23	1,570.39		
Total expenses		836.14	9,775.73		
Profit Before Tax		(90.16)	(2077.55)		
Tax expenses	28				
Current tax expense		100			
Deferred tax expense		(3.55)	(58.45)		
Taxes in respect of prior periods					
Total tax expenses		(3.55)	(58.45)		
Profit for the year		(86.61)	(2019.10)		
Other Comprehensive Income ('OCI')					
(i) Items that will not be reclassified subsequently to profit or loss					
Re-measurement gains/(losses) on defined benefit plans			15.29		
Income tax effect on the above			(3.85)		
(ii) Items that will be reclassified subsequently to profit or loss					
Total other comprehensive income		0.00	11.44		
Total comprehensive income for the year		(86.61)	(2007.67)		
Earnings per equity share (EPES)					
Basic EPS	24	(0.94)	(21.90)		
Diluted EPS		(0.94)	(21.90)		
Nominal value per equity share		10.00	10.00		

The accompanying notes form an integral part of these financial statements. This is the Statement of Profit and Loss referred to in our report of even date

For and onbehalf of the Board

HYDERABAD

G. Venkata Ramana Managing Director DIN: 00031873

Place: Hyderabad Date: 22-07-2025

CA INDIA

NSVR & ASSOCIATES LLP.,

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarter ended 30th June, 2025 Unaudited Standalone Financial Results of the Company pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of VINEET LABORATORIES LIMITED

- We have reviewed the accompanying statement of unaudited financial results of VINEET LABORATORIES LIMITED ('the Company') for the quarter ended 30th June 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations')
- 2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
- 4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements.

Continuation Sheet.

NSVR & ASSOCIATES up.,

CHARTERED ACCOUNTANTS

Our conclusion is not modified in respect of the above matters.

For NSVR & Associates LLP

Chartered Accountants

FRN 008801S/S200060

V Gangadhara Rao N

Partner

Membership No. 219486

UDIN: 25219486BMIRZV6004

Place: Hyderabad

Date: 22-07-2025